{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:43:45Z","timestamp":1792133025630,"version":"4.4.0"},"reference-count":84,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Endometrial cancer (EC) is a deleterious condition which strongly affects a woman\u2019s quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and\/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol acetate (MA), are the most employed agent in conservative treatment of early-stage EC. The metformin usage and hysteroscopic assessment is still under debate, despite promising results. Particularly strict and imperious attention should be given to the follow-up and psychological wellbeing of women, especially because of the double detrimental impairment: both EC and EC-related infertility consequences.<\/jats:p>","DOI":"10.3390\/ijms222111825","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:21:34Z","timestamp":1635805294000},"page":"11825","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-4269","authenticated-orcid":false,"given":"Giuseppe","family":"Gullo","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF UNIT, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Etrusco","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaspare","family":"Cucinella","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF UNIT, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Perino","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Villa Sofia Cervello Hospital, IVF UNIT, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Chiantera","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, University of Palermo, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1543-2802","authenticated-orcid":false,"given":"Antonio Simone","family":"Lagan\u00e0","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cFilippo Del Ponte\u201d Hospital, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-782X","authenticated-orcid":false,"given":"Rossella","family":"Tomaiuolo","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2824-5435","authenticated-orcid":false,"given":"Amerigo","family":"Vitagliano","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Gynaecological Clinic, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Giampaolino","sequence":"additional","affiliation":[{"name":"Department of Public Health, University Federico II of Naples, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Noventa","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Gynaecological Clinic, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Andrisani","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Gynaecological Clinic, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-0178","authenticated-orcid":false,"given":"Giovanni","family":"Buzzaccarini","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Gynaecological Clinic, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e8034","DOI":"10.1097\/MD.0000000000008034","article-title":"Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3802\/jgo.2019.30.e38","article-title":"Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999\u20132015","volume":"30","author":"Lim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_4","first-page":"663","article-title":"Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding","volume":"99","author":"Tabor","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2217\/fon.14.142","article-title":"Environmental (nongenetic) factors in gynecological cancers: Update and future perspectives","volume":"11","author":"Webb","year":"2015","journal-title":"Future Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s10552-010-9612-8","article-title":"Factors associated with Type I and Type II endometrial cancer","volume":"21","author":"Felix","year":"2010","journal-title":"Cancer Causes Control"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II endometrial cancers: Have they different risk factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/AOG.0000000000000563","article-title":"Family history and risk of endometrial cancer: A systematic review and meta-analysis","volume":"125","author":"Win","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000371758","article-title":"Hysteroscopy as a Valid Tool for Endometrial Pathology in Patients with Postmenopausal Bleeding or Asymptomatic Patients with a Thickened Endometrium: Hysteroscopic and Histological Results","volume":"79","author":"Loiacono","year":"2015","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/AOG.0000000000002261","article-title":"Accuracy of Endometrial Sampling in Endometrial Carcinoma: A Systematic Review and Meta-analysis","volume":"130","author":"Visser","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jmig.2016.03.017","article-title":"Sampling in Atypical Endometrial Hyperplasia: Which Method Results in the Lowest Underestimation of Endometrial Cancer? A Systematic Review and Meta-analysis","volume":"23","author":"Bourdel","year":"2016","journal-title":"J Minim. Invasive Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.23736\/S0026-4806.20.07125-6","article-title":"Novelties of ultrasound imaging for endometrial cancer preoperative workup","volume":"112","author":"Capozzi","year":"2021","journal-title":"Minerva Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kim, S.I., Lee, J.W., Lee, N., Lee, M., Kim, H.S., Chung, H.H., Kim, J.W., Park, N.H., Song, Y.S., and Seo, J.S. (2018). LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: Analysis of the cancer genome atlas data. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4429-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/0167482X.2016.1244186","article-title":"Comment on: \u201cNeeds and priorities of women with endometrial and cervical cancer\u201d","volume":"38","author":"Rapisarda","year":"2017","journal-title":"J. Psychosom. Obstet. Gynaecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5468\/ogs.19169","article-title":"Fertility-sparing treatment in early endometrial cancer: Current state and future strategies","volume":"63","author":"Obermair","year":"2020","journal-title":"Obstet. Gynecol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/AOG.0b013e3182964ce3","article-title":"Hormonal therapy for women with stage IA endometrial cancer of all grades","volume":"122","author":"Park","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ijgc-2018-000036","article-title":"Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer","volume":"29","author":"Chae","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejogrb.2018.01.030","article-title":"Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients","volume":"222","author":"Li","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"SGO Clinical Practice Endometrial Cancer Working Group, Burke, W.M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A.B., Brewer, M., Boruta, D., and Herzog, T.J. (2014). Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: A review and current management strategies: Part II. Gynecol. Oncol., 134, 393\u2013402.","DOI":"10.1016\/j.ygyno.2014.06.003"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejogrb.2017.04.015","article-title":"BGCS uterine cancer guidelines: Recommendations for practice","volume":"213","author":"Sundar","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1148\/radiology.212.3.r99au29711","article-title":"Radiologic staging in patients with endometrial cancer: A meta-analysis","volume":"212","author":"Kinkel","year":"1999","journal-title":"Radiology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2008.19.8150","article-title":"Safety of ovarian preservation in premenopausal women with endometrial cancer","volume":"27","author":"Wright","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","first-page":"718","article-title":"Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer","volume":"102","author":"Gotlieb","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0015-0282(01)02937-5","article-title":"Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction","volume":"77","author":"Lowe","year":"2002","journal-title":"Fertil. Steril."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/humrep\/dem088","article-title":"Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer","volume":"22","author":"Yamazawa","year":"2007","journal-title":"Hum. Reprod."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","article-title":"Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002)","volume":"49","author":"Park","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","article-title":"Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis","volume":"101","author":"Koskas","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3109\/09513590.2014.929658","article-title":"Desogestrel versus danazol as preoperative treatment for hysteroscopic surgery: A prospective, randomized evaluation","volume":"30","author":"Palmara","year":"2014","journal-title":"Gynecol. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3109\/09513590.2015.1128409","article-title":"Dienogest as preoperative treatment of submucous myomas for hysteroscopic surgery: A prospective, randomized study","volume":"32","author":"Giacobbe","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/17425255.2017.1297421","article-title":"S.; Vitale, S.G.; Granese, R.; Palmara, V.; Ban, Frange\u017e, H.; Vrta\u010dnik-Bokal, E.; Chiofalo, B.; Triolo, O. Clinical dynamics of Dienogest for the treatment of endometriosis: From bench to bedside","volume":"13","author":"Vitale","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00404-016-4244-1","article-title":"Endometrial preparation with Dienogest before hysteroscopic surgery: A systematic review","volume":"295","author":"Lagana","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_34","first-page":"137","article-title":"Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices","volume":"18","author":"Perino","year":"1987","journal-title":"Acta Eur. Fertil."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1245\/s10434-016-5699-9","article-title":"Levonorgestrel-releasing intrauterine systems versus oral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: A meta-analysis","volume":"24","author":"Yuk","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/AOG.0000000000002390","article-title":"Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device","volume":"131","author":"Pal","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/jjco\/hys171","article-title":"Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: Single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009)","volume":"42","author":"Kim","year":"2012","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000467","article-title":"Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential","volume":"25","author":"Pronin","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.ygyno.2004.10.031","article-title":"Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature","volume":"97","author":"Dhar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ijc.32753","article-title":"Predicted basal metabolic rate and cancer risk in the European prospective investigation into cancer and nutrition","volume":"147","author":"Kliemann","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygyno.2017.05.002","article-title":"Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer","volume":"146","author":"Park","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabres.2018.05.023","article-title":"Metformin in cancer","volume":"143","author":"Mallik","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1005-x","article-title":"Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism","volume":"568","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.orcp.2019.03.006","article-title":"Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis","volume":"13","author":"Yoon","year":"2019","journal-title":"Obes. Res. Clin. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.ygyno.2012.03.012","article-title":"Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase\/Akt dependent","volume":"125","author":"Wang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1055-9965.EPI-07-2686","article-title":"A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer","volume":"17","author":"Gunter","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ygyno.2012.03.032","article-title":"Insulin resistance: A significant risk factor of endometrial cancer","volume":"125","author":"Mu","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1158\/1940-6207.CAPR-17-0398","article-title":"Prospective randomized biomarker study of metformin and lifestyle intervention for prevention in obese women at increased risk for endometrial cancer","volume":"11","author":"Yates","year":"2018","journal-title":"Cancer Prev. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.3802\/jgo.2018.29.e35","article-title":"Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients","volume":"29","author":"Yang","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3802\/jgo.2019.30.e90","article-title":"Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients","volume":"30","author":"Mitsuhashi","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3332\/ecancer.2015.505","article-title":"Hysteroscopic surgery for conservative management in endometrial cancer: A review of the literature","volume":"9","author":"Alonso","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.fertnstert.2008.12.009","article-title":"Conservative surgical management of stage 1A endometrial carcinoma for fertility preservation","volume":"93","author":"Mazzon","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2010.10.004","article-title":"Conservative treatment of early endometrial cancer: Preliminary results of a pilot study","volume":"120","author":"Laurelli","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.jmig.2018.07.001","article-title":"Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial cancer: A retrospective study","volume":"26","author":"Giampaolino","year":"2019","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ygyno.2011.01.012","article-title":"The effect of operative hysteroscopy conducted befote progestins treatment in early stage endometrial cancer from the view of fertility","volume":"123","author":"Park","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0015-0282(03)01183-X","article-title":"Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma","volume":"80","author":"Jadoul","year":"2003","journal-title":"Fertil. Steril."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2004.06.045","article-title":"Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review","volume":"95","author":"Ramirez","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_58","unstructured":"American Cancer Society (2019). Surgery for Endometrial Cancer, American Cancer Society."},{"key":"ref_59","first-page":"1035","article-title":"Fertility preservation in women affected by gynaecological cancer: The importance of an integrated gynaecological and psychological approach","volume":"14","author":"Garzon","year":"2020","journal-title":"Ecancermedicalscience."},{"key":"ref_60","first-page":"68","article-title":"Quality of life in women with endometriosis: A narrative overview","volume":"111","author":"Barra","year":"2020","journal-title":"Minerva Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Gullo, G., Cucinella, G., Perino, A., Gullo, D., Segreto, D., Lagan\u00e0, A.S., Buzzaccarini, G., Donarelli, Z., Marino, A., and Allegra, A. (2021). The Gender Gap in the Diagnostic-Therapeutic Journey of the Infertile Couple. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18126184"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mce.2014.11.015","article-title":"Estrogen receptors in breast carcinogenesis and endocrine therapy","volume":"418","author":"Huang","year":"2015","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/15384047.2017.1394547","article-title":"Estrogen and insulin synergistically promote type 1 endometrial cancer progression","volume":"18","author":"Tian","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet, 386, 1341\u20131352.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/anie.201502227","article-title":"The \u201cother\u201d inositols and their phosphates: Synthesis, biology, and medicine (with recent advances in myo-inositol chemistry)","volume":"55","author":"Thomas","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1507\/endocrj.EJ13-0423","article-title":"Decreased myo-inositol to chiro-inositol (M\/C) ratios and increased M\/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls","volume":"61","author":"Heimark","year":"2014","journal-title":"Endocr. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/09513590.2015.1054802","article-title":"Reflections on inositol(s) for PCOS therapy: Steps toward success","volume":"31","author":"Nestler","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0006-291X(02)00313-3","article-title":"Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls","volume":"293","author":"Sun","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Facchinetti, F., Espinola, M.S.B., Dewailly, D., Ozay, A.C., Prapas, N., Vazquez-Levin, M., Wdowiak, A., and Unfer, V. (2020). Expert Group on Inositols in Preclinical and Clinical Research. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART). Trends Endocrinol. Metab.","DOI":"10.1016\/j.tem.2020.04.003"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Unfer, V., Dinicola, S., Lagan\u00e0, A.S., and Bizzarri, M. (2020). Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197157"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Genazzani, A., and Tarlatzis, B. (2016). The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences. Frontiers in Gynecological Endocrinology, Springer.","DOI":"10.1007\/978-3-319-23865-4"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Artini, P.G., Obino, M.E.R., Micelli, E., Malacarne, E., Vacca, C., Papini, F., and Cela, V. (2020). Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight\/obese PCOS women. Gynecol. Endocrinol.","DOI":"10.1080\/09513590.2020.1737007"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00404-014-3552-6","article-title":"Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol","volume":"291","author":"Barbaro","year":"2015","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.metabol.2008.05.008","article-title":"Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome","volume":"57","author":"Cheang","year":"2008","journal-title":"Metabolism"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","article-title":"The behavior of endometrial hyperplasia. A long-term study of \u201cuntreated\u201d hyperplasia in 170 patients","volume":"56","author":"Kurman","year":"1985","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.7314\/APJCP.2014.15.20.8975","article-title":"Functional investigation on aromatase in endometrial hyperplasia in polycystic ovary syndrome cases","volume":"15","author":"Zhao","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejogrb.2004.07.002","article-title":"Aromatase inhibitor anastrozole for treating endometrial hyperplasia in obese postmenopausal women","volume":"118","author":"Agorastos","year":"2005","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Iervolino, M., Lepore, E., Forte, G., Lagan\u00e0, A.S., Buzzaccarini, G., and Unfer, V. (2021). Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review. Nutrients, 13.","DOI":"10.3390\/nu13051677"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Gambioli, R., Forte, G., Buzzaccarini, G., Unfer, V., and Lagan\u00e0, A.S. (2021). Myo-Inositol as a Key Supporter of Fertility and Physiological Gestation. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060504"},{"key":"ref_80","first-page":"485","article-title":"Myo-inositol: From induction of ovulation to menopausal disorder management","volume":"67","author":"Gullo","year":"2015","journal-title":"Minerva Ginecol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","article-title":"Clinical actionability of molecular targets in endometrial cancer","volume":"19","author":"Urick","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Cavaliere, A.F., Perelli, F., Zaami, S., Piergentili, R., Mattei, A., Vizzielli, G., Scambia, G., Straface, G., Restaino, S., and Signore, F. (2021). Towards Personalized Medicine: Non-Coding RNAs and Endometrial Cancer. Healthcare, 9.","DOI":"10.3390\/healthcare9080965"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Piergentili, R., Zaami, S., Cavaliere, A.F., Signore, F., Scambia, G., Mattei, A., Marinelli, E., Gulia, C., and Perelli, F. (2021). Non-Coding RNAs as Prognostic Markers for Endometrial Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063151"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2018.06.028","article-title":"Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome","volume":"150","author":"Tortorella","year":"2018","journal-title":"Gynecol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11825\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:23:45Z","timestamp":1760167425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":84,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111825"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111825","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]}}}